Lymphoma, Non-Hodgkin  >>  Gazyva (obinutuzumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT01680991: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Completed
1
48
RoW
Obinutuzumab, RO5072759, GA101
Hoffmann-La Roche
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
12/14
12/14
GAUDI, NCT00825149: A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark relapsed/refractory follicular lymphoma
Jul 2013 - Jul 2013: relapsed/refractory follicular lymphoma
Checkmark P1 data in FL
More
Completed
1
137
Europe, RoW
Bendamustine, Cyclophosphamide, Doxorubicin, Fludarabine, Obinutuzumab, RO5072759, Prednisone, Vincristine
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
11/15
11/15

Download Options